Literature DB >> 16891459

Blockade of transforming growth factor-{beta} signaling in tumor-reactive CD8(+) T cells activates the antitumor immune response cycle.

Qiang Zhang1, Ximing J Yang, Shilajit D Kundu, Michael Pins, Borko Javonovic, Robert Meyer, Seong-Jin Kim, Norman M Greenberg, Timothy Kuzel, Richard Meagher, Yinglu Guo, Chung Lee.   

Abstract

Transforming growth factor-beta (TGF-beta) is a potent immunosuppressant. Overproduction of TGF-beta by tumor cells leads to evasion of host immune surveillance and tumor progression. Results of our early studies showed that adoptive transfer of tumor-reactive, TGF-beta-insensitive CD8(+) T cells into immunocompetent mice was able to eradicate lung metastasis of mouse prostate cancer. The present study was conducted with three objectives. (a) We tested if this technology could be applied to the treatment of solid xenograft tumors in allogeneic immunodeficient hosts. (b) We determined relevant variables in the tumor microenvironment with the treatment. (c) We tested if immune cells other than CD8(+) T cells were required for the antitumor effect. Mouse prostate cancer cells, TRAMP-C2 of the C57BL/6 strain, grown in immunodeficient allogeneic hosts of BALB/c strain, were used as a xenograft model. Tumor-reactive CD8(+) T cells from C57BL/6 mice were isolated, expanded ex vivo, and rendered insensitive to TGF-beta by introducing a dominant-negative TGF-beta type II receptor vector. Seven days following s.c. injection of TRAMP-C2 cells (5 x 10(5)) into the flank of male BALB/c-Rag1(-/-) mice, tumor-reactive, TGF-beta-insensitive CD8(+) T cells (1.5 x 10(7)) were transferred with and without the cotransfer of an equal number of CD8-depleted splenocytes from C57BL/6 donors. Naive CD8(+) T cells or green fluorescent protein-empty vector-transfected tumor-reactive CD8(+) T cells were transferred as controls. Forty days following the transfer, the average tumor weight in animals that received cotransfer of tumor-reactive, TGF-beta-insensitive CD8(+) T cells and CD8-depleted splenocytes was at least 50% less than that in animals of all other groups (P < 0.05). Tumors in animals of the former group showed a massive infiltration of CD8(+) T cells. This was associated with secretion of relevant cytokines, decreased tumor proliferation, reduced angiogenesis, and increased tumor apoptosis. Based on these results, we postulated a concept of antitumor immune response cycle in tumor immunology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891459     DOI: 10.1158/1535-7163.MCT-06-0109

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  26 in total

Review 1.  Negative regulators in homeostasis of naïve peripheral T cells.

Authors:  Jaime F Modiano; Lisa D S Johnson; Donald Bellgrau
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 2.  Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease.

Authors:  Qiang Zhang; Brian T Helfand; Benedito A Carneiro; Weijun Qin; Ximing J Yang; Chung Lee; Weipeng Zhang; Francis J Giles; Massimo Cristofanilli; Timothy M Kuzel
Journal:  Eur Urol       Date:  2017-12-21       Impact factor: 20.096

3.  TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.

Authors:  Daniel R Principe; Brian DeCant; Emman Mascariñas; Elizabeth A Wayne; Andrew M Diaz; Naomi Akagi; Rosa Hwang; Boris Pasche; David W Dawson; Deyu Fang; David J Bentrem; Hidayatullah G Munshi; Barbara Jung; Paul J Grippo
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

Review 4.  Vicious cycle of TGF-β signaling in tumor progression and metastasis.

Authors:  Qiang Zhang; Nengwang Yu; Chung Lee
Journal:  Am J Clin Exp Urol       Date:  2014-07-12

5.  Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells.

Authors:  Lizhou Jia; Shiwu Zhang; Yanfen Ye; Xin Li; Imelda Mercado-Uribe; Robert C Bast; Jinsong Liu
Journal:  Cancer Lett       Date:  2012-08-15       Impact factor: 8.679

6.  Tgf-Beta superfamily receptors-targets for antiangiogenic therapy?

Authors:  Jasmin Otten; Carsten Bokemeyer; Walter Fiedler
Journal:  J Oncol       Date:  2010-05-13       Impact factor: 4.375

Review 7.  Synergistic immunologic targets for the treatment of prostate cancer.

Authors:  Karen M Doersch; Kelvin A Moses; Warren E Zimmer
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-20

Review 8.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

9.  An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments.

Authors:  Jeong-Seok Nam; Masaki Terabe; Mizuko Mamura; Mi-Jin Kang; Helen Chae; Christina Stuelten; Ethan Kohn; Binwu Tang; Helen Sabzevari; Miriam R Anver; Scott Lawrence; David Danielpour; Scott Lonning; Jay A Berzofsky; Lalage M Wakefield
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

10.  Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.

Authors:  Hannes Neuwirt; Martin Puhr; Frédéric R Santer; Martin Susani; Wolfgang Doppler; Gemma Marcias; Veronika Rauch; Maria Brugger; Alfred Hobisch; Lukas Kenner; Zoran Culig
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.